Basic Information

Common Name
B-hCD19 MC38
Aliases
CD19, CD19 molecule, B4, CVID3
Stock Number
310706
Cell Type/ Disease
Colon Carcinoma
Species/ Strain
Mus musculus, C57BL/6
Notice
Biocytogen provides engineering service to generate the humanized tumor cell lines from customer’s own cell lines. Our humanized tumor cell lines are for pharmacology services ONLY.

Description

The mouse Cd19 gene was replaced by human CD19 coding sequence in B-hCD19 MC38 cells. Human CD19 is highly expressed on the surface of B-hCD19 MC38 cells.

Application

B-hCD19 MC38 cells have the capability to establish tumors in vivo and can be used for efficacy studies.

Target strategy

The exogenous promoter and human CD19 coding sequence was inserted to replace part of murine exon 2 and all of exons 3~12. The insertion disrupts the endogenous murine Cd19 gene, resulting in a non-functional transcript.

Protein expression analysis

CD19 expression analysis in B-hCD19 MC38 cells by flow cytometry. Single cell suspensions from wild-type MC38 and B-hCD19 MC38 cultures were stained with species-specific anti-CD19 antibody. Human CD19 was detected on the surface of B-hCD19 MC38 cells but not wild-type MC38 cells. The 2-G1 clone of B-hCD19 MC38 cells was used for in vivo experiments.

Tumor growth curve

Subcutaneous homograft tumor growth of B-hCD19 MC38 cells. B-hCD19 MC38 cells (5×105) and wild-type MC38 cells (5×105) were subcutaneously implanted into C57BL/6 mice (female, n=5). Tumor volume and body weight were measured twice a week. (A) Average tumor volume ± SEM. (B)  Body weight (Mean± SEM). Volume was expressed in mm3 using the formula: V=0.5 X long diameter X short diameter2. As shown in panel A, B-hCD19 MC38 cells were able to establish tumors in vivo and can be used for efficacy studies.